Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
75%(3 trials)

Phase Distribution

Ph phase_3
1
20%
Ph phase_4
2
40%
Ph not_applicable
1
20%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(4)

Detailed Status

Completed4
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (25.0%)
Phase 42 (50.0%)
N/A1 (25.0%)

Trials by Status

completed480%
not_yet_recruiting120%

Recent Activity

0 active trials
Showing 5 of 5
not_yet_recruitingnot_applicable

A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome

NCT07406932
completed

Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients

NCT01656343
completedphase_4

Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation

NCT00377962
completedphase_4

ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients

NCT00170846
completedphase_3

RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency

NCT00267189

Clinical Trials (5)

Showing 5 of 5 trials
NCT07406932Not Applicable

A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome

Not Yet Recruiting
NCT01656343

Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients

Completed
NCT00377962Phase 4

Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation

Completed
NCT00170846Phase 4

ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients

Completed
NCT00267189Phase 3

RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5